Chronic Atrophic Gastritis Clinical Trial
Official title:
Follow-up Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis Based on Histological Evaluation
The purpose of this study is to evaluate efficacy of Chinese medicine treatment for chronic atrophic gastritis. It is a multi-center, randomized, placebo-controlled trial.
A prospective, double-blind, randomized, placebo-controlled, multi-center trial is carried out in this study.The sample size is 468 patients ( 312 in treatment group, 156 in control group). The investigators will screen the patients for inclusion according to the inclusion and exclusion criteria. All patients detect of H.pylori, undergo upper digestive endoscopy and biopsies for histological investigation. Patients infected of H.pylori must receive H.pylori eradication therapy under the guidance of Kyoto global consensus report on H.pylori gastritis. Then they are assigned to treatment group or control group with an allocation ratio of 2:1. Patients intreatment group take the traditional Chinese medicine prescription, while the control group take simulate granule of the prescription. Both two groups are under symptomatic treatment. Treatment duration lasts 24 weeks. Investigators also follow up another 24 weeks. Histological changes are used as the primary outcome index. Endoscopy findings, symptoms are assessed. Serum level of pepsinogen and patient-reported outcome instrument are also administered during the study. All biopsy specimens are collected to build the biological specimen bank. Central blinded histological assessment (Histological diagnosis is determined independently by three experienced pathologists who are blinded to the information of the patients.) are used to insure the accuracy and consistency. Tele-medicine and information management system is established to help achieve follow-up interviews. Random numbers are generated by SAS 9.4 software. The subjects, caregivers, investigators and outcomes assessors in this study are all blinded. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06085677 -
The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
|
||
Active, not recruiting |
NCT05808010 -
Clinical Study of Umbilical Cord Blood Mononuclear Cell Therapy for the Treatment of Chronic Atrophic Gastritis
|
N/A | |
Terminated |
NCT01444014 -
YF476 and Type I Gastric Carcinoids (Norway)
|
Phase 2 | |
Recruiting |
NCT05493124 -
Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis
|
Early Phase 1 | |
Completed |
NCT01339169 -
YF476 and Type I Gastric Carcinoids
|
Phase 2 | |
Active, not recruiting |
NCT06267703 -
Multi-omics Analyses on Etiology and Early Detection of Stomach Cancer Precursor Lesions
|
||
Recruiting |
NCT03597672 -
Early Detection and Screening Strategy of Gatric Cancer in Sichuan Province-A Prospective Cohort Study (WCH-GC-SIGES-01)
|
||
Recruiting |
NCT05388890 -
Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation
|
||
Active, not recruiting |
NCT02782949 -
Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
|
Phase 2 |